BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29299356)

  • 1. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm.
    Clasen SC; Ky B; O'Quinn R; Giantonio B; Teitelbaum U; Carver JR
    J Gastrointest Oncol; 2017 Dec; 8(6):970-979. PubMed ID: 29299356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.
    Chakrabarti S; Sara J; Lobo R; Eiring R; Finnes H; Mitchell J; Hartgers M; Okano A; Halfdanarson T; Grothey A
    Clin Colorectal Cancer; 2019 Mar; 18(1):52-57. PubMed ID: 30396850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity.
    Kasi A; Gaudel P; Lekkala M; Al-Rajabi R; Saeed A; Sun W; Porter C
    J Oncol Pharm Pract; 2023 Dec; 29(8):1951-1956. PubMed ID: 36883259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge.
    Vater LB; Lefebvre B; Turk A; Clasen SC
    Curr Oncol Rep; 2022 Jul; 24(7):943-950. PubMed ID: 35347593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.
    Osterlund P; Kinos S; Pfeiffer P; Salminen T; Kwakman JJM; Frödin JE; Shah CH; Sorbye H; Ristamäki R; Halonen P; Soveri LM; Heervä E; Ålgars A; Bärlund M; Hagman H; McDermott R; O'Reilly M; Röckert R; Liposits G; Kallio R; Flygare P; Teske AJ; van Werkhoven E; Punt CJA; Glimelius B
    ESMO Open; 2022 Jun; 7(3):100427. PubMed ID: 35798468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm.
    Zafar A; Drobni ZD; Lei M; Gongora CA; Quinaglia T; Lou UY; Mosarla R; Murphy SP; Jones-O'Connor M; Mahmood A; Hartmann S; Gilman HK; Weekes CD; Nipp R; Clark JR; Clark JW; Blaszkowsky LS; Tavares E; Neilan TG
    PLoS One; 2022; 17(4):e0265767. PubMed ID: 35390017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Vasospasm and Microcirculatory Dysfunction in Fluoropyrimidine-Induced Ischemic Heart Disease.
    Fabin N; Bergami M; Cenko E; Bugiardini R; Manfrini O
    J Clin Med; 2022 Feb; 11(5):. PubMed ID: 35268333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusion.
    Redman JM; Rhea LP; Brofferio A; Whelpley M; Gulley JL; Gatti-Mays ME; McMahon S; Cordes LM; Strauss J
    J Gastrointest Oncol; 2019 Oct; 10(5):1010-1014. PubMed ID: 31602339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Fluorouracil Rechallenge After Cardiotoxicity.
    Desai A; Mohammed T; Patel KN; Almnajam M; Kim AS
    Am J Case Rep; 2020 Aug; 21():e924446. PubMed ID: 32860674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral versus intravenous fluoropyrimidines for colorectal cancer.
    Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoropyrimidine-Associated Cardiotoxicity.
    Kanduri J; More LA; Godishala A; Asnani A
    Cardiol Clin; 2019 Nov; 37(4):399-405. PubMed ID: 31587781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy for advanced gastric cancer.
    Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.
    Layoun ME; Wickramasinghe CD; Peralta MV; Yang EH
    Curr Oncol Rep; 2016 Jun; 18(6):35. PubMed ID: 27113369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study.
    Raber I; Warack S; Kanduri J; Pribish A; Godishala A; Abovich A; Orbite A; Dommaraju S; Frazer M; Peters ML; Asnani A
    Oncologist; 2020 Mar; 25(3):e606-e609. PubMed ID: 32162823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
    Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
    Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
    Ransom D; Wilson K; Fournier M; Simes RJ; Gebski V; Yip D; Tebbutt N; Karapetis CS; Ferry D; Gordon S; Price TJ
    Ann Oncol; 2014 Jan; 25(1):117-21. PubMed ID: 24299960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of ABC transporters in fluoropyrimidine-based chemotherapy response.
    Nies AT; Magdy T; Schwab M; Zanger UM
    Adv Cancer Res; 2015; 125():217-43. PubMed ID: 25640272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac toxicity with capecitabine, vinorelbine and trastuzumab therapy: case report and review of fluoropyrimidine-related cardiotoxicity.
    Le Brun-Ly V; Martin J; Venat-Bouvet L; Darodes N; Labourey JL; Genet D; Tubiana-Mathieu N
    Oncology; 2009; 76(5):322-5. PubMed ID: 19307737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report.
    Akpek G; Hartshorn KL
    Cancer Chemother Pharmacol; 1999; 43(2):157-61. PubMed ID: 9923822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.
    Manfredi S; Turpin A; Malka D; Barbier E; Laurent-Puig P; Zaanan A; Dahan L; Lièvre A; Phelip JM; Michel P; Hautefeuille V; Legoux JL; Lepage C; Tougeron D; Aparicio T
    Dig Liver Dis; 2020 Oct; 52(10):1143-1147. PubMed ID: 32747302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.